CTEV — Claritev Corp
NYSE · Health Care · Health Care
- Latest Close
- $20.3
- 30-Day Move
- -47.2%
- Market Cap
- $289M
- Shares Outstanding
- 16,550,000
- P/B Ratio
- 2.83
- ROE
- -1958.8%
Claritev Corp
A read-only Alphactor snapshot forClaritev Corp. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-23
Topline snapshot
Latest Close
$20.3
30-Day Move
-47.2%
Market Cap
$289M
Shares Outstanding
16,550,000
P/B Ratio
2.83
ROE
-1958.8%
$20.30
-47.2%last 90 delayed daily bars
90D High
$44.50
90D Low
$12.04
Avg Volume
195,977
Gross margin is running at 73.8%, which gives a quick read on operating quality before you open the full model.
Net margin is -29.4%, useful for comparing CTEV against peers in Health Care.
CTEV is down 47.2% over the last 30 trading days shown on this page.
Latest operating income is $45M, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$13.76
Rule of 40
2.5%
Latest Close
$20.3
30-Day Move
-47.2%
Market Cap
$289M
Shares Outstanding
16,550,000
P/B Ratio
2.83
ROE
-1958.8%
ROA
-5.8%
Gross Margin
73.8%
Operating Margin
2.1%
Net Margin
-29.4%
Debt / Equity
53.83
Current Ratio
0.86
Latest Revenue
$965M
Revenue
$965M
Gross Profit
$649M
Operating Income
$45M
Net Income
$-284M
Gross Margin
7375.0%
Net Margin
-2945.0%
Current Ratio
0.86
Debt / Equity
53.83
Fair Value
$13.76
Upside / Downside
-32.2%
Signal
Overvalued
Implied Growth
21.0%
EV/Rev
$13.76
Growth Assumption
-3.7%
Discount Rate
11.3%
Terminal Growth
2.0%
Base FCF
$117M
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
High growth priced in
Altman Z
-0.44
Distress
Piotroski
5
Moderate (4-6)
Cash Conversion
-0.41x
Rule of 40
2.5%
Concerning
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $1.1B | $334M | $-573M | $283M |
| 2023-12-31 | $962M | $171M | $-92M | $63M |
| 2024-12-31 | $931M | $108M | $-1.6B | $-11M |
| 2025-12-31 | $965M | $45M | $-284M | $-12M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
Vanguard Group
Filed 2025-11-07
$27M
+8.3%
Charles Schwab
Filed 2025-11-10
$12M
+17.5%
Geode Capital Management
Filed 2025-11-12
$9M
+7.2%
Invesco
Filed 2025-08-13
$8M
+1133.2%
Renaissance Technologies
Filed 2025-11-13
$6M
+86.1%
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Healthcare Investing: Pharma, Biotech, and the FDA Calendar
A framework for navigating healthcare stocks across pharma, biotech, and medical devices, with emphasis on regulatory catalysts and pipeline valuation.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.